Acadia Pharmaceuticals
ACAD
ACAD
227 hedge funds and large institutions have $2.75B invested in Acadia Pharmaceuticals in 2022 Q4 according to their latest regulatory filings, with 30 funds opening new positions, 73 increasing their positions, 81 reducing their positions, and 23 closing their positions.
New
Increased
Maintained
Reduced
Closed
more call options, than puts
Call options by funds: $ | Put options by funds: $
more funds holding in top 10
Funds holding in top 10: →
more first-time investments, than exits
New positions opened: | Existing positions closed:
more capital invested
Capital invested by funds: $ → $
2% more funds holding
Funds holding: 222 → 227 (+5)
2.03% more ownership
Funds ownership: 94.18% → 96.21% (+2%)
10% less repeat investments, than reductions
Existing positions increased: 73 | Existing positions reduced: 81
Holders
227
Holding in Top 10
6
Calls
$11.3M
Puts
$4M
Top Buyers
| 1 | +$17.4M | |
| 2 | +$15.8M | |
| 3 | +$15M | |
| 4 |
Man Group
London,
United Kingdom
|
+$14.6M |
| 5 |
Nomura Holdings
Tokyo,
Japan
|
+$13.5M |
Top Sellers
| 1 | -$35M | |
| 2 | -$20.7M | |
| 3 | -$12.3M | |
| 4 |
T. Rowe Price Associates
Baltimore,
Maryland
|
-$9.57M |
| 5 |
Squarepoint
New York
|
-$7.79M |